Despite continued rumblings of uncertainty surrounding the implementation of ICD-10, pharmaceutical manufacturers should continue preparing to reduce the risk for provider claims challenges, payer errors, and other access concerns that could compromise continuity of therapy. While healthcare facilities and physician […]
Read MoreFedEx’s SenseAware device One of the longstanding essentials of transporting temperature-sensitive pharma products has been documenting the conditions experienced during a shipment: usually, the temperature of the product payload; increasingly, conditions such as humidity, the status of containers holding the […]
Read MoreSpringtime, the annual BIO meeting, and the general upswing in both commercial and investor activity in biotech (see p. 8) has brought a raft of new announcements of manufacturing capacity. Interestingly, most of the new announcements involve non-US companies expanding […]
Read MoreThe annual report from Evaluate Pharma, World Preview 2015, Outlook to 2020, compiles a variety of data on research, drug pipelines, and current and projected sales. By its count, the No. 1 biopharma company in the world both in 2014 […]
Read MoreBack in the day—the year 1990. Heading into the last decade of the 20th century, George H.W. Bush was in office presiding over Operation Desert Storm. The first webpage was written on the World Wide Web. Microsoft released Windows 3.0 […]
Read MorePhase III, as we all know, is the last step before a drug is submitted to FDA for approval; if FDA okays it at that point, it comes to market as soon as the drug sponsor can make the commercialization […]
Read MoreMerck’s Januvia There are powerful therapies from the pharma industry to combat diabetes, but it continues to be a challenge to public health in the US, and to societies around the world moving up the ladder from developing to developed. […]
Read MoreThe classic view of new product launches in the pharma/biotech industries has been similar to a Broadway theater opening: all the performance details have been worked out, a splashy promotional effort has been made, and, on opening night, the critics […]
Read MoreToday’s clinical trial landscape is saturated with vendor-outsourced trials, generating multimillion-dollar program budgets for sponsors. The constant reported budget swings and cost overruns puzzle senior leadership. What is so difficult about forecasting and managing trial budgets? Due to the inherent […]
Read MoreToday’s patient population is markedly different from that of generations past. Americans are turning age 65 at a rate of 8,000 per day*, a statistic projected to continue for the next 18 years, and multitudes of individuals among all age […]
Read More